Broadly Reactive IgG Responses to Heterologous H5 Prime-Boost Influenza Vaccination Are Shaped by Antigenic Relatedness to Priming Strains
The antigenic shift and draft of hemagglutinin (HA) in influenza viruses is accepted as one of the major reasons for immune evasion. The analysis of B cell immune responses to influenza infection and vaccination is complicated by the impact of exposure history and antibody cross-reactions between an...
Saved in:
Published in | mBio Vol. 12; no. 4; p. e0044921 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Society for Microbiology
31.08.2021
|
Subjects | |
Online Access | Get full text |
ISSN | 2150-7511 2150-7511 |
DOI | 10.1128/mBio.00449-21 |
Cover
Abstract | The antigenic shift and draft of hemagglutinin (HA) in influenza viruses is accepted as one of the major reasons for immune evasion. The analysis of B cell immune responses to influenza infection and vaccination is complicated by the impact of exposure history and antibody cross-reactions between antigenically similar influenza strains.
Prime-boost vaccinations of humans with different H5 strains have generated broadly protective antibody levels. However, the effect of an individual’s H5 exposure history on antibody responses to subsequent H5 vaccination is poorly understood. To investigate this, we analyzed the IgG responses to H5 influenza A/Indonesia/5/2005 (Ind05) virus vaccination in three cohorts: (i) a doubly primed group that had received two H5 virus vaccinations, namely, against influenza A/Vietnam/203/2004 (Vie04) virus 5 years prior and A/Hong Kong/156/1997 (HK97) 11 years prior to the Ind05 vaccination; (ii) a singly primed group that had received a vaccination against Vie04 virus 5 years prior to the Ind05 vaccination; and (iii) an H5-naive group that received two doses of the Ind05 vaccine 28 days apart. Hemagglutinin (HA)-reactive IgG levels were estimated by a multiplex assay against an HA panel that included 21 H5 strains and 9 other strains representing the H1, H3, H7, and H9 subtypes. Relative HA antibody landscapes were generated to quantitatively analyze the magnitude and breadth of antibody binding after vaccination. We found that short-interval priming and boosting with the Ind05 vaccine in the naive group generated a low anti-H5 response. Both primed groups generated robust antibody responses reactive to a broad range of H5 strains after receiving a booster injection of Ind05 vaccine; IgG antibody levels persisted longer in subjects who had been doubly primed years ago. Notably, the IgG responses were strongest against the first priming H5 strain, which reflects influenza virus immune imprinting. Finally, the broad anti-H5 IgG response was stronger against strains having a small antigenic distance from the initial priming strain.
IMPORTANCE
The antigenic shift and draft of hemagglutinin (HA) in influenza viruses is accepted as one of the major reasons for immune evasion. The analysis of B cell immune responses to influenza infection and vaccination is complicated by the impact of exposure history and antibody cross-reactions between antigenically similar influenza strains. To assist in such analyses, the influenza “antibody landscape” method has been used to analyze and visualize the relationship of antibody-mediated immunity to antigenic distances between influenza strains. In this study, we describe a “relative antibody landscape” method that calculates the antigenic distance between the vaccine influenza strain and other H5 strains and uses this relative antigenic distance to plot the anti-H5 IgG levels postvaccination. This new method quantitatively estimates and visualizes the correlation between the humoral response to a particular influenza strain and the antigenic distance from other strains. Our findings demonstrate the effect of a subject’s H5 exposure history on H5 vaccine responses quantified by the relative antibody landscape method. |
---|---|
AbstractList | Prime-boost vaccinations of humans with different H5 strains have generated broadly protective antibody levels. However, the effect of an individual’s H5 exposure history on antibody responses to subsequent H5 vaccination is poorly understood. To investigate this, we analyzed the IgG responses to H5 influenza A/Indonesia/5/2005 (Ind05) virus vaccination in three cohorts: (i) a doubly primed group that had received two H5 virus vaccinations, namely, against influenza A/Vietnam/203/2004 (Vie04) virus 5 years prior and A/Hong Kong/156/1997 (HK97) 11 years prior to the Ind05 vaccination; (ii) a singly primed group that had received a vaccination against Vie04 virus 5 years prior to the Ind05 vaccination; and (iii) an H5-naive group that received two doses of the Ind05 vaccine 28 days apart. Hemagglutinin (HA)-reactive IgG levels were estimated by a multiplex assay against an HA panel that included 21 H5 strains and 9 other strains representing the H1, H3, H7, and H9 subtypes. Relative HA antibody landscapes were generated to quantitatively analyze the magnitude and breadth of antibody binding after vaccination. We found that short-interval priming and boosting with the Ind05 vaccine in the naive group generated a low anti-H5 response. Both primed groups generated robust antibody responses reactive to a broad range of H5 strains after receiving a booster injection of Ind05 vaccine; IgG antibody levels persisted longer in subjects who had been doubly primed years ago. Notably, the IgG responses were strongest against the first priming H5 strain, which reflects influenza virus immune imprinting. Finally, the broad anti-H5 IgG response was stronger against strains having a small antigenic distance from the initial priming strain. Prime-boost vaccinations of humans with different H5 strains have generated broadly protective antibody levels. However, the effect of an individual's H5 exposure history on antibody responses to subsequent H5 vaccination is poorly understood. To investigate this, we analyzed the IgG responses to H5 influenza A/Indonesia/5/2005 (Ind05) virus vaccination in three cohorts: (i) a doubly primed group that had received two H5 virus vaccinations, namely, against influenza A/Vietnam/203/2004 (Vie04) virus 5 years prior and A/Hong Kong/156/1997 (HK97) 11 years prior to the Ind05 vaccination; (ii) a singly primed group that had received a vaccination against Vie04 virus 5 years prior to the Ind05 vaccination; and (iii) an H5-naive group that received two doses of the Ind05 vaccine 28 days apart. Hemagglutinin (HA)-reactive IgG levels were estimated by a multiplex assay against an HA panel that included 21 H5 strains and 9 other strains representing the H1, H3, H7, and H9 subtypes. Relative HA antibody landscapes were generated to quantitatively analyze the magnitude and breadth of antibody binding after vaccination. We found that short-interval priming and boosting with the Ind05 vaccine in the naive group generated a low anti-H5 response. Both primed groups generated robust antibody responses reactive to a broad range of H5 strains after receiving a booster injection of Ind05 vaccine; IgG antibody levels persisted longer in subjects who had been doubly primed years ago. Notably, the IgG responses were strongest against the first priming H5 strain, which reflects influenza virus immune imprinting. Finally, the broad anti-H5 IgG response was stronger against strains having a small antigenic distance from the initial priming strain. The antigenic shift and draft of hemagglutinin (HA) in influenza viruses is accepted as one of the major reasons for immune evasion. The analysis of B cell immune responses to influenza infection and vaccination is complicated by the impact of exposure history and antibody cross-reactions between antigenically similar influenza strains. To assist in such analyses, the influenza "antibody landscape" method has been used to analyze and visualize the relationship of antibody-mediated immunity to antigenic distances between influenza strains. In this study, we describe a "relative antibody landscape" method that calculates the antigenic distance between the vaccine influenza strain and other H5 strains and uses this relative antigenic distance to plot the anti-H5 IgG levels postvaccination. This new method quantitatively estimates and visualizes the correlation between the humoral response to a particular influenza strain and the antigenic distance from other strains. Our findings demonstrate the effect of a subject's H5 exposure history on H5 vaccine responses quantified by the relative antibody landscape method. Prime-boost vaccinations of humans with different H5 strains have generated broadly protective antibody levels. However, the effect of an individual's H5 exposure history on antibody responses to subsequent H5 vaccination is poorly understood. To investigate this, we analyzed the IgG responses to H5 influenza A/Indonesia/5/2005 (Ind05) virus vaccination in three cohorts: (i) a doubly primed group that had received two H5 virus vaccinations, namely, against influenza A/Vietnam/203/2004 (Vie04) virus 5 years prior and A/Hong Kong/156/1997 (HK97) 11 years prior to the Ind05 vaccination; (ii) a singly primed group that had received a vaccination against Vie04 virus 5 years prior to the Ind05 vaccination; and (iii) an H5-naive group that received two doses of the Ind05 vaccine 28 days apart. Hemagglutinin (HA)-reactive IgG levels were estimated by a multiplex assay against an HA panel that included 21 H5 strains and 9 other strains representing the H1, H3, H7, and H9 subtypes. Relative HA antibody landscapes were generated to quantitatively analyze the magnitude and breadth of antibody binding after vaccination. We found that short-interval priming and boosting with the Ind05 vaccine in the naive group generated a low anti-H5 response. Both primed groups generated robust antibody responses reactive to a broad range of H5 strains after receiving a booster injection of Ind05 vaccine; IgG antibody levels persisted longer in subjects who had been doubly primed years ago. Notably, the IgG responses were strongest against the first priming H5 strain, which reflects influenza virus immune imprinting. Finally, the broad anti-H5 IgG response was stronger against strains having a small antigenic distance from the initial priming strain. IMPORTANCE The antigenic shift and draft of hemagglutinin (HA) in influenza viruses is accepted as one of the major reasons for immune evasion. The analysis of B cell immune responses to influenza infection and vaccination is complicated by the impact of exposure history and antibody cross-reactions between antigenically similar influenza strains. To assist in such analyses, the influenza "antibody landscape" method has been used to analyze and visualize the relationship of antibody-mediated immunity to antigenic distances between influenza strains. In this study, we describe a "relative antibody landscape" method that calculates the antigenic distance between the vaccine influenza strain and other H5 strains and uses this relative antigenic distance to plot the anti-H5 IgG levels postvaccination. This new method quantitatively estimates and visualizes the correlation between the humoral response to a particular influenza strain and the antigenic distance from other strains. Our findings demonstrate the effect of a subject's H5 exposure history on H5 vaccine responses quantified by the relative antibody landscape method.Prime-boost vaccinations of humans with different H5 strains have generated broadly protective antibody levels. However, the effect of an individual's H5 exposure history on antibody responses to subsequent H5 vaccination is poorly understood. To investigate this, we analyzed the IgG responses to H5 influenza A/Indonesia/5/2005 (Ind05) virus vaccination in three cohorts: (i) a doubly primed group that had received two H5 virus vaccinations, namely, against influenza A/Vietnam/203/2004 (Vie04) virus 5 years prior and A/Hong Kong/156/1997 (HK97) 11 years prior to the Ind05 vaccination; (ii) a singly primed group that had received a vaccination against Vie04 virus 5 years prior to the Ind05 vaccination; and (iii) an H5-naive group that received two doses of the Ind05 vaccine 28 days apart. Hemagglutinin (HA)-reactive IgG levels were estimated by a multiplex assay against an HA panel that included 21 H5 strains and 9 other strains representing the H1, H3, H7, and H9 subtypes. Relative HA antibody landscapes were generated to quantitatively analyze the magnitude and breadth of antibody binding after vaccination. We found that short-interval priming and boosting with the Ind05 vaccine in the naive group generated a low anti-H5 response. Both primed groups generated robust antibody responses reactive to a broad range of H5 strains after receiving a booster injection of Ind05 vaccine; IgG antibody levels persisted longer in subjects who had been doubly primed years ago. Notably, the IgG responses were strongest against the first priming H5 strain, which reflects influenza virus immune imprinting. Finally, the broad anti-H5 IgG response was stronger against strains having a small antigenic distance from the initial priming strain. IMPORTANCE The antigenic shift and draft of hemagglutinin (HA) in influenza viruses is accepted as one of the major reasons for immune evasion. The analysis of B cell immune responses to influenza infection and vaccination is complicated by the impact of exposure history and antibody cross-reactions between antigenically similar influenza strains. To assist in such analyses, the influenza "antibody landscape" method has been used to analyze and visualize the relationship of antibody-mediated immunity to antigenic distances between influenza strains. In this study, we describe a "relative antibody landscape" method that calculates the antigenic distance between the vaccine influenza strain and other H5 strains and uses this relative antigenic distance to plot the anti-H5 IgG levels postvaccination. This new method quantitatively estimates and visualizes the correlation between the humoral response to a particular influenza strain and the antigenic distance from other strains. Our findings demonstrate the effect of a subject's H5 exposure history on H5 vaccine responses quantified by the relative antibody landscape method. Prime-boost vaccinations of humans with different H5 strains have generated broadly protective antibody levels. However, the effect of an individual’s H5 exposure history on antibody responses to subsequent H5 vaccination is poorly understood. To investigate this, we analyzed the IgG responses to H5 influenza A/Indonesia/5/2005 (Ind05) virus vaccination in three cohorts: (i) a doubly primed group that had received two H5 virus vaccinations, namely, against influenza A/Vietnam/203/2004 (Vie04) virus 5 years prior and A/Hong Kong/156/1997 (HK97) 11 years prior to the Ind05 vaccination; (ii) a singly primed group that had received a vaccination against Vie04 virus 5 years prior to the Ind05 vaccination; and (iii) an H5-naive group that received two doses of the Ind05 vaccine 28 days apart. Hemagglutinin (HA)-reactive IgG levels were estimated by a multiplex assay against an HA panel that included 21 H5 strains and 9 other strains representing the H1, H3, H7, and H9 subtypes. Relative HA antibody landscapes were generated to quantitatively analyze the magnitude and breadth of antibody binding after vaccination. We found that short-interval priming and boosting with the Ind05 vaccine in the naive group generated a low anti-H5 response. Both primed groups generated robust antibody responses reactive to a broad range of H5 strains after receiving a booster injection of Ind05 vaccine; IgG antibody levels persisted longer in subjects who had been doubly primed years ago. Notably, the IgG responses were strongest against the first priming H5 strain, which reflects influenza virus immune imprinting. Finally, the broad anti-H5 IgG response was stronger against strains having a small antigenic distance from the initial priming strain. IMPORTANCE The antigenic shift and draft of hemagglutinin (HA) in influenza viruses is accepted as one of the major reasons for immune evasion. The analysis of B cell immune responses to influenza infection and vaccination is complicated by the impact of exposure history and antibody cross-reactions between antigenically similar influenza strains. To assist in such analyses, the influenza “antibody landscape” method has been used to analyze and visualize the relationship of antibody-mediated immunity to antigenic distances between influenza strains. In this study, we describe a “relative antibody landscape” method that calculates the antigenic distance between the vaccine influenza strain and other H5 strains and uses this relative antigenic distance to plot the anti-H5 IgG levels postvaccination. This new method quantitatively estimates and visualizes the correlation between the humoral response to a particular influenza strain and the antigenic distance from other strains. Our findings demonstrate the effect of a subject’s H5 exposure history on H5 vaccine responses quantified by the relative antibody landscape method. ABSTRACT Prime-boost vaccinations of humans with different H5 strains have generated broadly protective antibody levels. However, the effect of an individual’s H5 exposure history on antibody responses to subsequent H5 vaccination is poorly understood. To investigate this, we analyzed the IgG responses to H5 influenza A/Indonesia/5/2005 (Ind05) virus vaccination in three cohorts: (i) a doubly primed group that had received two H5 virus vaccinations, namely, against influenza A/Vietnam/203/2004 (Vie04) virus 5 years prior and A/Hong Kong/156/1997 (HK97) 11 years prior to the Ind05 vaccination; (ii) a singly primed group that had received a vaccination against Vie04 virus 5 years prior to the Ind05 vaccination; and (iii) an H5-naive group that received two doses of the Ind05 vaccine 28 days apart. Hemagglutinin (HA)-reactive IgG levels were estimated by a multiplex assay against an HA panel that included 21 H5 strains and 9 other strains representing the H1, H3, H7, and H9 subtypes. Relative HA antibody landscapes were generated to quantitatively analyze the magnitude and breadth of antibody binding after vaccination. We found that short-interval priming and boosting with the Ind05 vaccine in the naive group generated a low anti-H5 response. Both primed groups generated robust antibody responses reactive to a broad range of H5 strains after receiving a booster injection of Ind05 vaccine; IgG antibody levels persisted longer in subjects who had been doubly primed years ago. Notably, the IgG responses were strongest against the first priming H5 strain, which reflects influenza virus immune imprinting. Finally, the broad anti-H5 IgG response was stronger against strains having a small antigenic distance from the initial priming strain. IMPORTANCE The antigenic shift and draft of hemagglutinin (HA) in influenza viruses is accepted as one of the major reasons for immune evasion. The analysis of B cell immune responses to influenza infection and vaccination is complicated by the impact of exposure history and antibody cross-reactions between antigenically similar influenza strains. To assist in such analyses, the influenza “antibody landscape” method has been used to analyze and visualize the relationship of antibody-mediated immunity to antigenic distances between influenza strains. In this study, we describe a “relative antibody landscape” method that calculates the antigenic distance between the vaccine influenza strain and other H5 strains and uses this relative antigenic distance to plot the anti-H5 IgG levels postvaccination. This new method quantitatively estimates and visualizes the correlation between the humoral response to a particular influenza strain and the antigenic distance from other strains. Our findings demonstrate the effect of a subject’s H5 exposure history on H5 vaccine responses quantified by the relative antibody landscape method. The antigenic shift and draft of hemagglutinin (HA) in influenza viruses is accepted as one of the major reasons for immune evasion. The analysis of B cell immune responses to influenza infection and vaccination is complicated by the impact of exposure history and antibody cross-reactions between antigenically similar influenza strains. Prime-boost vaccinations of humans with different H5 strains have generated broadly protective antibody levels. However, the effect of an individual’s H5 exposure history on antibody responses to subsequent H5 vaccination is poorly understood. To investigate this, we analyzed the IgG responses to H5 influenza A/Indonesia/5/2005 (Ind05) virus vaccination in three cohorts: (i) a doubly primed group that had received two H5 virus vaccinations, namely, against influenza A/Vietnam/203/2004 (Vie04) virus 5 years prior and A/Hong Kong/156/1997 (HK97) 11 years prior to the Ind05 vaccination; (ii) a singly primed group that had received a vaccination against Vie04 virus 5 years prior to the Ind05 vaccination; and (iii) an H5-naive group that received two doses of the Ind05 vaccine 28 days apart. Hemagglutinin (HA)-reactive IgG levels were estimated by a multiplex assay against an HA panel that included 21 H5 strains and 9 other strains representing the H1, H3, H7, and H9 subtypes. Relative HA antibody landscapes were generated to quantitatively analyze the magnitude and breadth of antibody binding after vaccination. We found that short-interval priming and boosting with the Ind05 vaccine in the naive group generated a low anti-H5 response. Both primed groups generated robust antibody responses reactive to a broad range of H5 strains after receiving a booster injection of Ind05 vaccine; IgG antibody levels persisted longer in subjects who had been doubly primed years ago. Notably, the IgG responses were strongest against the first priming H5 strain, which reflects influenza virus immune imprinting. Finally, the broad anti-H5 IgG response was stronger against strains having a small antigenic distance from the initial priming strain. IMPORTANCE The antigenic shift and draft of hemagglutinin (HA) in influenza viruses is accepted as one of the major reasons for immune evasion. The analysis of B cell immune responses to influenza infection and vaccination is complicated by the impact of exposure history and antibody cross-reactions between antigenically similar influenza strains. To assist in such analyses, the influenza “antibody landscape” method has been used to analyze and visualize the relationship of antibody-mediated immunity to antigenic distances between influenza strains. In this study, we describe a “relative antibody landscape” method that calculates the antigenic distance between the vaccine influenza strain and other H5 strains and uses this relative antigenic distance to plot the anti-H5 IgG levels postvaccination. This new method quantitatively estimates and visualizes the correlation between the humoral response to a particular influenza strain and the antigenic distance from other strains. Our findings demonstrate the effect of a subject’s H5 exposure history on H5 vaccine responses quantified by the relative antibody landscape method. |
Author | Li, Dongmei Wiltse, Alexander Sangster, Mark Y. Treanor, John J. Zand, Martin S. Wang, Jiong Perry, Sheldon Hilchey, Shannon P. |
Author_xml | – sequence: 1 givenname: Jiong surname: Wang fullname: Wang, Jiong organization: Department of Medicine, Division of Nephrology, University of Rochester Medical Center, Rochester, New York, USA – sequence: 2 givenname: Dongmei surname: Li fullname: Li, Dongmei organization: Informatics Core, Clinical, and Translational Science Institute, University of Rochester, Rochester, New York, USA – sequence: 3 givenname: Sheldon surname: Perry fullname: Perry, Sheldon organization: Department of Medicine, Division of Nephrology, University of Rochester Medical Center, Rochester, New York, USA – sequence: 4 givenname: Shannon P. surname: Hilchey fullname: Hilchey, Shannon P. organization: Department of Medicine, Division of Nephrology, University of Rochester Medical Center, Rochester, New York, USA – sequence: 5 givenname: Alexander surname: Wiltse fullname: Wiltse, Alexander organization: Department of Medicine, Division of Nephrology, University of Rochester Medical Center, Rochester, New York, USA – sequence: 6 givenname: John J. surname: Treanor fullname: Treanor, John J. organization: Department of Medicine, Division of Infectious Diseases, University of Rochester Medical Center, Rochester, New York, USA – sequence: 7 givenname: Mark Y. surname: Sangster fullname: Sangster, Mark Y. organization: Department of Immunology, Vaccine Center, University of Rochester Medical Center, Rochester, New York, USA – sequence: 8 givenname: Martin S. orcidid: 0000-0002-7095-8682 surname: Zand fullname: Zand, Martin S. organization: Department of Medicine, Division of Nephrology, University of Rochester Medical Center, Rochester, New York, USA, Informatics Core, Clinical, and Translational Science Institute, University of Rochester, Rochester, New York, USA, Rochester Center for Health Informatics, University of Rochester Medical Center, Rochester, New York, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34225490$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kk1vEzEQhi1UREvokSvyEVXa4o_drHNBaipoIlUCUeBqzdqTraONHWynUvgJ_GqcpEUtAl_8Me88Gs87L8mRDx4Jec3ZOedCvVtNXThnrK4nleDPyIngDavahvOjR-djcprSkpUlJVeSvSDHshaiqSfshPyaxgB22NIvCCa7O6Tz_qpc0jr4hInmQGeYMYYh9GGT6Kyhn6NbYTUNIWU694thg_4n0O9gjPOQXfD0IiK9uYU1Wtpt6YXPrkfvTMEOkNF6THvwDuR8T29yBOfTK_J8AUPC0_t9RL59_PD1clZdf7qaX15cV1ArlauFkQBcTTrVKbC16GCMlitR1xJV2y0MihKTrYCxEsw0nRVClh5hZ-3YjCdyROYHrg2w1OtSBMStDuD0_iHEXkPMzgyojbQMmraVqhF1IzmUdCm4KtROWaUK6_2Btd50K7QGffnL8AT6NOLdre7DnVY1G8tS2Ii8vQfE8GODKeuVSwaHATyWfutik5qwpi3ejcjZQQppJfQybKIvbdKc6d0s6N0s6P0saMGL-M3jwv5U9OB8EciDwMSQUsSFNi7v7du5MfwXW_2V9QD-t_43OETSjg |
CitedBy_id | crossref_primary_10_1093_infdis_jiac022 crossref_primary_10_1093_infdis_jiad276 crossref_primary_10_1080_21645515_2022_2128014 crossref_primary_10_1172_JCI162192 crossref_primary_10_3389_fimmu_2021_696370 crossref_primary_10_3390_pathogens12020169 crossref_primary_10_1038_s41541_024_00874_4 crossref_primary_10_3389_fimmu_2023_1253626 crossref_primary_10_3390_vaccines9121465 crossref_primary_10_1016_j_vaccine_2024_126530 crossref_primary_10_3390_vaccines10060980 |
Cites_doi | 10.1016/j.coviro.2016.12.004 10.1128/JVI.06930-11 10.1056/NEJMp048343 10.1016/j.immuni.2019.06.024 10.1155/2019/3053869 10.1038/nature11414 10.1073/pnas.1111497108 10.1016/j.coi.2018.04.001 10.1038/s41594-018-0025-9 10.1038/srep46426 10.1016/j.vaccine.2009.11.002 10.1093/infdis/jiv210 10.1038/cr.2017.154 10.1038/ni.3684 10.1093/infdis/jix173 10.1093/infdis/jis402 10.1073/pnas.0813390106 10.1371/journal.pone.0049704 10.1016/j.coviro.2013.07.007 10.1126/science.1097211 10.1371/journal.pone.0050830 10.4049/jimmunol.1801149 10.1128/JVI.05397-11 10.1155/2019/9287120 10.1128/JVI.00169-19 10.1056/NEJMc2101667 10.1086/590916 10.1093/infdis/jit180 10.1371/journal.pone.0129858 10.1056/NEJMra0707279 10.1038/s41541-019-0114-8 10.1093/infdis/jiu616 10.1371/journal.pone.0095496 10.1126/science.1256427 10.1016/S0264-410X(00)00395-9 10.1073/pnas.1906613117 10.1126/science.aag1322 10.1128/JVI.00137-12 10.3201/eid1407.071681 10.1073/pnas.1414070111 10.1093/infdis/jiq093 10.1016/j.cell.2015.04.028 10.1371/journal.pone.0193680 10.3390/pathogens8040238 10.1073/pnas.1200039109 10.3888/tmj.17-7 10.1128/JVI.00700-11 |
ContentType | Journal Article |
Copyright | Copyright © 2021 Wang et al. Copyright © 2021 Wang et al. 2021 Wang et al. |
Copyright_xml | – notice: Copyright © 2021 Wang et al. – notice: Copyright © 2021 Wang et al. 2021 Wang et al. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
DOI | 10.1128/mBio.00449-21 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Open Access Full Text url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2150-7511 |
Editor | Rappuoli, Rino |
Editor_xml | – sequence: 1 givenname: Rino surname: Rappuoli fullname: Rappuoli, Rino |
ExternalDocumentID | oai_doaj_org_article_c3d0a57738524531a6933218c5bb8d88 PMC8406322 mBio00449-21 34225490 10_1128_mBio_00449_21 |
Genre | Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NIAID NIH HHS grantid: R01 AI129518 – fundername: NIAID NIH HHS grantid: R21 AI138500 – fundername: NCATS NIH HHS grantid: UL1 TR002001 – fundername: HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) grantid: R21 AI138500 funderid: https://doi.org/10.13039/100000060 – fundername: Division of Intramural Research, National Institute of Allergy and Infectious Diseases (DIR, NIAID) grantid: R01 AI129518 funderid: https://doi.org/10.13039/100006492 – fundername: HHS | NIH | National Center for Advancing Translational Sciences (NCATS) grantid: TR002001 funderid: https://doi.org/10.13039/100006108 – fundername: ; grantid: R01 AI129518 – fundername: ; grantid: TR002001 – fundername: ; grantid: R21 AI138500 |
GroupedDBID | --- 0R~ 53G 5VS AAFWJ AAGFI AAUOK AAYXX ADBBV AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BTFSW CITATION DIK E3Z EBS FRP GROUPED_DOAJ GX1 H13 HYE HZ~ KQ8 M48 O5R O5S O9- OK1 P2P PGMZT RHI RNS RPM RSF CGR CUY CVF ECM EIF NPM - 0R ADACO BXI HZ M~E RHF 7X8 5PM |
ID | FETCH-LOGICAL-a488t-fc3aa189b8b8ad42ba6ed182443e87bfce29b8372a6820c5bd223004ebdd6c693 |
IEDL.DBID | DOA |
ISSN | 2150-7511 |
IngestDate | Wed Aug 27 01:31:33 EDT 2025 Thu Aug 21 18:21:03 EDT 2025 Fri Jul 11 12:06:39 EDT 2025 Tue Dec 28 13:57:58 EST 2021 Thu Apr 03 07:05:47 EDT 2025 Tue Jul 01 01:52:48 EDT 2025 Thu Apr 24 22:56:36 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | HA imprinting hemagglutinin (HA) antigenic distance original antigenic sin (OAS) influenza virus antibody landscape H5 monovalent influenza vaccine (MIV) |
Language | English |
License | This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. https://creativecommons.org/licenses/by/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-a488t-fc3aa189b8b8ad42ba6ed182443e87bfce29b8372a6820c5bd223004ebdd6c693 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Jiong Wang and Dongmei Li contributed equally to this work. Author order for the co-first authors was decided by the primary focus of the paper; being biological, Dr. Wang, who designed and performed the experiments, was listed as first, and Dr. Li, who performed the statistical analysis, was listed second. Present address: John J. Treanor, Biomedical Advanced Research and Development Authority (BARDA)/HHS/ASPR, Influenza and Emerging Diseases Division 21J14, Washington, DC, USA. |
ORCID | 0000-0002-7095-8682 |
OpenAccessLink | https://doaj.org/article/c3d0a57738524531a6933218c5bb8d88 |
PMID | 34225490 |
PQID | 2548905703 |
PQPubID | 23479 |
PageCount | 15 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_c3d0a57738524531a6933218c5bb8d88 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8406322 proquest_miscellaneous_2548905703 asm2_journals_10_1128_mBio_00449_21 pubmed_primary_34225490 crossref_citationtrail_10_1128_mBio_00449_21 crossref_primary_10_1128_mBio_00449_21 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-08-31 |
PublicationDateYYYYMMDD | 2021-08-31 |
PublicationDate_xml | – month: 08 year: 2021 text: 2021-08-31 day: 31 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
PublicationTitle | mBio |
PublicationTitleAbbrev | mBio |
PublicationTitleAlternate | mBio |
PublicationYear | 2021 |
Publisher | American Society for Microbiology |
Publisher_xml | – name: American Society for Microbiology |
References | e_1_3_2_26_2 e_1_3_2_49_2 e_1_3_2_28_2 e_1_3_2_41_2 e_1_3_2_20_2 e_1_3_2_43_2 e_1_3_2_22_2 e_1_3_2_45_2 Francis JT (e_1_3_2_17_2) 1953; 66 e_1_3_2_24_2 e_1_3_2_47_2 Francis JT (e_1_3_2_16_2) 1960; 104 e_1_3_2_9_2 e_1_3_2_37_2 e_1_3_2_7_2 e_1_3_2_18_2 e_1_3_2_39_2 e_1_3_2_10_2 e_1_3_2_31_2 e_1_3_2_52_2 e_1_3_2_5_2 e_1_3_2_12_2 e_1_3_2_33_2 e_1_3_2_3_2 e_1_3_2_14_2 e_1_3_2_35_2 e_1_3_2_50_2 e_1_3_2_27_2 e_1_3_2_48_2 e_1_3_2_29_2 e_1_3_2_40_2 e_1_3_2_21_2 e_1_3_2_42_2 e_1_3_2_23_2 e_1_3_2_44_2 e_1_3_2_25_2 e_1_3_2_46_2 e_1_3_2_15_2 e_1_3_2_38_2 e_1_3_2_8_2 e_1_3_2_6_2 e_1_3_2_19_2 e_1_3_2_30_2 e_1_3_2_53_2 e_1_3_2_32_2 e_1_3_2_51_2 e_1_3_2_11_2 e_1_3_2_34_2 e_1_3_2_4_2 e_1_3_2_13_2 e_1_3_2_36_2 e_1_3_2_2_2 (B22) 2008; 14 Krammer, F, Srivastava, K, Alshammary, H, Amoako, AA, Awawda, MH, Beach, KF, Bermudez-Gonzalez, MC, Bielak, DA, Carreno, JM, Chernet, RL, Eaker, LQ, Ferreri, ED, Floda, DL, Gleason, CR, Hamburger, JZ, Jiang, K, Kleiner, G, Jurczyszak, D, Matthews, JC, Mendez, WA, Nabeel, I, Mulder, LCF, Raskin, AJ, Russo, KT, Salimbangon, AT, Saksena, M, Shin, AS, Singh, G, Sominsky, LA, Stadlbauer, D, Wajnberg, A, Simon, V (B13) 2021; 384 Krause, JC, Tsibane, T, Tumpey, TM, Huffman, CJ, Basler, CF, Crowe, JJE (B47) 2011; 85 Pica, N, Hai, R, Krammer, F, Wang, TT, Maamary, J, Eggink, D, Tan, GS, Krause, JC, Moran, T, Stein, CR, Banach, D, Wrammert, J, Belshe, RB, Garcia-Sastre, A, Palese, P (B31) 2012; 109 Ledgerwood, JE, Zephir, K, Hu, Z, Wei, CJ, Chang, L, Enama, ME, Hendel, CS, Sitar, S, Bailer, RT, Koup, RA, Mascola, JR, Nabel, GJ, Graham, BS (B38) 2013; 208 Khurana, S, Coyle, EM, Dimitrova, M, Castellino, F, Nicholson, K, Del Giudice, G, Golding, H (B42) 2014; 9 Cobey, S, Hensley, SE (B17) 2017; 22 Wang, J, Hilchey, SP, Hyrien, O, Huertas, N, Perry, S, Ramanunninair, M, Bucher, D, Zand, MS (B25) 2015; 10 Abdel-Ghafar, A-N, Chotpitayasunondh, T, Gao, Z, Hayden, FG, Nguyen, DH, de Jong, MD, Naghdaliyev, A, Peiris, JS, Shindo, N, Soeroso, S, Uyeki, TM (B23) 2008; 358 Treanor, JJ, Wilkinson, BE, Masseoud, F, Hu-Primmer, J, Battaglia, R, O'Brien, D, Wolff, M, Rabinovich, G, Blackwelder, W, Katz, JM (B6) 2001; 19 Nachbagauer, R, Palese, P (B14) 2018; 53 Whittle, JR, Zhang, R, Khurana, S, King, LR, Manischewitz, J, Golding, H, Dormitzer, PR, Haynes, BF, Walter, EB, Moody, MA, Kepler, TB, Liao, HX, Harrison, SC (B48) 2011; 108 Gostic, KM, Ambrose, M, Worobey, M, Lloyd-Smith, JO (B2) 2016; 354 Baer, J, Santiago, F, Yang, H, Wu, H, Holden-Wiltse, J, Treanor, J, Topham, DJ (B12) 2010; 28 Wang, J, Hilchey, SP, DeDiego, M, Perry, S, Hyrien, O, Nogales, A, Garigen, J, Amanat, F, Huertas, N, Krammer, F, Martinez-Sobrido, L, Topham, DJ, Treanor, JJ, Sangster, MY, Zand, MS (B33) 2018; 13 Ellebedy, AH, Nachbagauer, R, Jackson, KJL, Dai, YN, Han, J, Alsoussi, WB, Davis, CW, Stadlbauer, D, Rouphael, N, Chromikova, V, McCausland, M, Chang, CY, Cortese, M, Bower, M, Chennareddy, C, Schmitz, AJ, Zarnitsyna, VI, Lai, L, Rajabhathor, A, Kazemian, C, Antia, R, Mulligan, MJ, Ward, AB, Fremont, DH, Boyd, SD, Pulendran, B, Krammer, F, Ahmed, R (B45) 2020; 117 Halliley, JL, Khurana, S, Krammer, F, Fitzgerald, T, Coyle, EM, Chung, KY, Baker, SF, Yang, H, Martinez-Sobrido, L, Treanor, JJ, Subbarao, K, Golding, H, Topham, DJ, Sangster, MY (B40) 2015; 212 Belshe, RB, Frey, SE, Graham, I, Mulligan, MJ, Edupuganti, S, Jackson, LA, Wald, A, Poland, G, Jacobson, R, Keyserling, HL, Spearman, P, Hill, H, Wolff, M (B37) 2011; 203 Andrews, SF, Chambers, MJ, Schramm, CA, Plyler, J, Raab, JE, Kanekiyo, M, Gillespie, RA, Ransier, A, Darko, S, Hu, J, Chen, X, Yassine, HM, Boyington, JC, Crank, MC, Chen, GL, Coates, E, Mascola, JR, Douek, DC, Graham, BS, Ledgerwood, JE, McDermott, AB (B39) 2019; 51 Wang, J, Wiltse, A, Zand, MS (B36) 2019; 8 Francis, JT, Davenport, FM, Hennessy, AV (B16) 1953; 66 Zand, MS, Wang, J, Hilchey, S (B29) 2015; 17 B4 B5 Li, D, Wang, J, Treanor, JJ, Zand, MS (B28) 2019; 2019 Van Hoeven, N, Fox, CB, Granger, B, Evers, T, Joshi, SW, Nana, GI, Evans, SC, Lin, S, Liang, H, Liang, L, Nakajima, R, Felgner, PL, Bowen, RA, Marlenee, N, Hartwig, A, Baldwin, SL, Coler, RN, Tomai, M, Elvecrog, J, Reed, SG, Carter, D (B44) 2017; 7 Ekiert, DC, Kashyap, AK, Steel, J, Rubrum, A, Bhabha, G, Khayat, R, Lee, JH, Dillon, MA, O’Neil, RE, Faynboym, AM, Horowitz, M, Horowitz, L, Ward, AB, Palese, P, Webby, R, Lerner, RA, Bhatt, RR, Wilson, IA (B46) 2012; 489 Levine, MZ, Holiday, C, Jefferson, S, Gross, FL, Liu, F, Li, S, Friel, D, Boutet, P, Innis, BL, Mallett, CP, Tumpey, TM, Stevens, J, Katz, JM (B43) 2019; 4 Subbarao, K (B8) 2018; 28 Krammer, F, Palese, P (B21) 2013; 3 Wu, NC, Wilson, IA (B32) 2018; 25 Nachbagauer, R, Choi, A, Hirsh, A, Margine, I, Iida, S, Barrera, A, Ferres, M, Albrecht, RA, Garcia-Sastre, A, Bouvier, NM, Ito, K, Medina, RA, Palese, P, Krammer, F (B20) 2017; 18 Goji, NA, Nolan, C, Hill, H, Wolff, M, Noah, DL, Williams, TB, Rowe, T, Treanor, JJ (B11) 2008; 198 Hai, R, Krammer, F, Tan, GS, Pica, N, Eggink, D, Maamary, J, Margine, I, Albrecht, RA, Palese, P (B52) 2012; 86 Couch, RB, Decker, WK, Utama, B, Atmar, RL, Nino, D, Feng, JQ, Halpert, MM, Air, GM (B10) 2012; 7 Zhang, A, Stacey, HD, Mullarkey, CE, Miller, MS (B18) 2019; 202 Monto, AS, Malosh, RE, Petrie, JG, Martin, ET (B19) 2017; 215 Ohshima, N, Iba, Y, Kubota-Koketsu, R, Asano, Y, Okuno, Y, Kurosawa, Y (B49) 2011; 85 Galli, G, Medini, D, Borgogni, E, Zedda, L, Bardelli, M, Malzone, C, Nuti, S, Tavarini, S, Sammicheli, C, Hilbert, AK, Brauer, V, Banzhoff, A, Rappuoli, R, Del Giudice, G, Castellino, F (B41) 2009; 106 B51 Francis, JT (B15) 1960; 104 Tesini, BL, Kanagaiah, P, Wang, J, Hahn, M, Halliley, JL, Chaves, FA, Nguyen, PQT, Nogales, A, DeDiego, ML, Anderson, CS, Ellebedy, AH, Strohmeier, S, Krammer, F, Yang, H, Bandyopadhyay, S, Ahmed, R, Treanor, JJ, Martinez-Sobrido, L, Golding, H, Khurana, S, Zand, MS, Topham, DJ, Sangster, MY (B34) 2019; 93 Monto, AS (B3) 2005; 352 Patel, SM, Atmar, RL, El Sahly, HM, Guo, K, Hill, H, Keitel, WA (B7) 2012; 206 Schmidt, AG, Therkelsen, MD, Stewart, S, Kepler, TB, Liao, HX, Moody, MA, Haynes, BF, Harrison, SC (B50) 2015; 161 Ellebedy, AH, Krammer, F, Li, GM, Miller, MS, Chiu, C, Wrammert, J, Chang, CY, Davis, CW, McCausland, M, Elbein, R, Edupuganti, S, Spearman, P, Andrews, SF, Wilson, PC, Garcia-Sastre, A, Mulligan, MJ, Mehta, AK, Palese, P, Ahmed, R (B35) 2014; 111 Nayak, JL, Richards, KA, Yang, H, Treanor, JJ, Sant, AJ (B24) 2015; 211 Zhou, F, Wang, G, Buchy, P, Cai, Z, Chen, H, Chen, Z, Cheng, G, Wan, XF, Deubel, V, Zhou, P (B1) 2012; 86 Fonville, JM, Wilks, SH, James, SL, Fox, A, Ventresca, M, Aban, M, Xue, L, Jones, TC, Le, NM, Pham, QT, Tran, ND, Wong, Y, Mosterin, A, Katzelnick, LC, Labonte, D, Le, TT, van der Net, G, Skepner, E, Russell, CA, Kaplan, TD, Rimmelzwaan, GF, Masurel, N, de Jong, JC, Palache, A, Beyer, WE, Le, QM, Nguyen, TH, Wertheim, HF, Hurt, AC, Osterhaus, AD, Barr, IG, Fouchier, RA, Horby, PW, Smith, DJ (B26) 2014; 346 Couch, RB, Patel, SM, Wade-Bowers, CL, Nino, D (B9) 2012; 7 Li, D, Wang, J, Garigen, J, Treanor, JJ, Zand, MS (B27) 2019; 2019 Smith, DJ, Lapedes, AS, de Jong, JC, Bestebroer, TM, Rimmelzwaan, GF, Osterhaus, AD, Fouchier, RA (B30) 2004; 305 |
References_xml | – ident: e_1_3_2_18_2 doi: 10.1016/j.coviro.2016.12.004 – ident: e_1_3_2_2_2 doi: 10.1128/JVI.06930-11 – ident: e_1_3_2_4_2 doi: 10.1056/NEJMp048343 – ident: e_1_3_2_40_2 doi: 10.1016/j.immuni.2019.06.024 – ident: e_1_3_2_6_2 – ident: e_1_3_2_29_2 doi: 10.1155/2019/3053869 – ident: e_1_3_2_47_2 doi: 10.1038/nature11414 – ident: e_1_3_2_49_2 doi: 10.1073/pnas.1111497108 – ident: e_1_3_2_5_2 – ident: e_1_3_2_15_2 doi: 10.1016/j.coi.2018.04.001 – ident: e_1_3_2_33_2 doi: 10.1038/s41594-018-0025-9 – ident: e_1_3_2_45_2 doi: 10.1038/srep46426 – ident: e_1_3_2_13_2 doi: 10.1016/j.vaccine.2009.11.002 – ident: e_1_3_2_41_2 doi: 10.1093/infdis/jiv210 – ident: e_1_3_2_9_2 doi: 10.1038/cr.2017.154 – ident: e_1_3_2_21_2 doi: 10.1038/ni.3684 – ident: e_1_3_2_20_2 doi: 10.1093/infdis/jix173 – ident: e_1_3_2_8_2 doi: 10.1093/infdis/jis402 – ident: e_1_3_2_52_2 – ident: e_1_3_2_42_2 doi: 10.1073/pnas.0813390106 – volume: 104 start-page: 572 year: 1960 ident: e_1_3_2_16_2 article-title: On the doctrine of original antigenic sin publication-title: Proc Am Philos Soc – ident: e_1_3_2_10_2 doi: 10.1371/journal.pone.0049704 – ident: e_1_3_2_22_2 doi: 10.1016/j.coviro.2013.07.007 – ident: e_1_3_2_31_2 doi: 10.1126/science.1097211 – ident: e_1_3_2_11_2 doi: 10.1371/journal.pone.0050830 – ident: e_1_3_2_19_2 doi: 10.4049/jimmunol.1801149 – ident: e_1_3_2_50_2 doi: 10.1128/JVI.05397-11 – ident: e_1_3_2_28_2 doi: 10.1155/2019/9287120 – ident: e_1_3_2_35_2 doi: 10.1128/JVI.00169-19 – ident: e_1_3_2_14_2 doi: 10.1056/NEJMc2101667 – volume: 66 start-page: 231 year: 1953 ident: e_1_3_2_17_2 article-title: A serological recapitulation of human infection with different strains of influenza virus publication-title: Trans Assoc Am Physicians – ident: e_1_3_2_12_2 doi: 10.1086/590916 – ident: e_1_3_2_39_2 doi: 10.1093/infdis/jit180 – ident: e_1_3_2_26_2 doi: 10.1371/journal.pone.0129858 – ident: e_1_3_2_24_2 doi: 10.1056/NEJMra0707279 – ident: e_1_3_2_44_2 doi: 10.1038/s41541-019-0114-8 – ident: e_1_3_2_25_2 doi: 10.1093/infdis/jiu616 – ident: e_1_3_2_43_2 doi: 10.1371/journal.pone.0095496 – ident: e_1_3_2_27_2 doi: 10.1126/science.1256427 – ident: e_1_3_2_7_2 doi: 10.1016/S0264-410X(00)00395-9 – ident: e_1_3_2_46_2 doi: 10.1073/pnas.1906613117 – ident: e_1_3_2_3_2 doi: 10.1126/science.aag1322 – ident: e_1_3_2_53_2 doi: 10.1128/JVI.00137-12 – ident: e_1_3_2_23_2 doi: 10.3201/eid1407.071681 – ident: e_1_3_2_36_2 doi: 10.1073/pnas.1414070111 – ident: e_1_3_2_38_2 doi: 10.1093/infdis/jiq093 – ident: e_1_3_2_51_2 doi: 10.1016/j.cell.2015.04.028 – ident: e_1_3_2_34_2 doi: 10.1371/journal.pone.0193680 – ident: e_1_3_2_37_2 doi: 10.3390/pathogens8040238 – ident: e_1_3_2_32_2 doi: 10.1073/pnas.1200039109 – ident: e_1_3_2_30_2 doi: 10.3888/tmj.17-7 – ident: e_1_3_2_48_2 doi: 10.1128/JVI.00700-11 – volume: 2019 start-page: 9287120 year: 2019 ident: B27 article-title: Continuous readout versus titer-based assays of influenza vaccine trials: sensitivity, specificity, and false discovery rates publication-title: Comput Math Methods Med doi: 10.1155/2019/9287120 – volume: 161 start-page: 1026 year: 2015 end-page: 1034 ident: B50 article-title: Viral receptor-binding site antibodies with diverse germline origins publication-title: Cell doi: 10.1016/j.cell.2015.04.028 – volume: 4 start-page: 22 year: 2019 ident: B43 article-title: Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost publication-title: NPJ Vaccines doi: 10.1038/s41541-019-0114-8 – volume: 203 start-page: 666 year: 2011 end-page: 673 ident: B37 article-title: Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant publication-title: J Infect Dis doi: 10.1093/infdis/jiq093 – volume: 18 start-page: 464 year: 2017 end-page: 473 ident: B20 article-title: Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins publication-title: Nat Immunol doi: 10.1038/ni.3684 – ident: B5 article-title: World Health Organization . 2015 . Influenza at the human-animal interface (summary and assessment as of 6 January 2015) . WHO , Geneva, Switzerland . https://www.who.int/influenza/human_animal_interface/Influenza_Summary_IRA_HA_interface_6January2015.pdf?ua=1 . – volume: 93 year: 2019 ident: B34 article-title: Broad hemagglutinin-specific memory B cell expansion by seasonal influenza virus infection reflects early-life imprinting and adaptation to the infecting virus publication-title: J Virol doi: 10.1128/JVI.00169-19 – volume: 358 start-page: 261 year: 2008 end-page: 273 ident: B23 article-title: Update on avian influenza A (H5N1) virus infection in humans publication-title: N Engl J Med doi: 10.1056/NEJMra0707279 – volume: 7 year: 2012 ident: B9 article-title: A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine publication-title: PLoS One doi: 10.1371/journal.pone.0049704 – ident: B4 article-title: Centers for Disease Control and Prevention . 2018 . Highly pathogenic Asian avian influenza A(H5N1) virus . Centers for Disease Control and Prevention , Atlanta, GA . https://www.cdc.gov/flu/avianflu/h5n1-virus.htm . – volume: 10 year: 2015 ident: B25 article-title: Multi-dimensional measurement of antibody-mediated heterosubtypic immunity to influenza publication-title: PLoS One doi: 10.1371/journal.pone.0129858 – volume: 208 start-page: 418 year: 2013 end-page: 422 ident: B38 article-title: Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect publication-title: J Infect Dis doi: 10.1093/infdis/jit180 – volume: 22 start-page: 105 year: 2017 end-page: 111 ident: B17 article-title: Immune history and influenza virus susceptibility publication-title: Curr Opin Virol doi: 10.1016/j.coviro.2016.12.004 – volume: 109 start-page: 2573 year: 2012 end-page: 2578 ident: B31 article-title: Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1200039109 – volume: 215 start-page: 1782 year: 2017 end-page: 1788 ident: B19 article-title: The doctrine of original antigenic sin: separating good from evil publication-title: J Infect Dis doi: 10.1093/infdis/jix173 – volume: 13 year: 2018 ident: B33 article-title: Broad cross-reactive IgG responses elicited by adjuvanted vaccination with recombinant influenza hemagglutinin (rHA) in ferrets and mice publication-title: PLoS One doi: 10.1371/journal.pone.0193680 – volume: 17 start-page: 17-7 year: 2015 ident: B29 article-title: Graphical representation of proximity measures for multidimensional data: classical and metric multidimensional scaling publication-title: Math J doi: 10.3888/tmj.17-7 – volume: 25 start-page: 115 year: 2018 end-page: 121 ident: B32 article-title: Structural insights into the design of novel anti-influenza therapies publication-title: Nat Struct Mol Biol doi: 10.1038/s41594-018-0025-9 – volume: 9 year: 2014 ident: B42 article-title: Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization publication-title: PLoS One doi: 10.1371/journal.pone.0095496 – volume: 28 start-page: 1 year: 2018 end-page: 2 ident: B8 article-title: Avian influenza H7N9 viruses: a rare second warning publication-title: Cell Res doi: 10.1038/cr.2017.154 – volume: 66 start-page: 231 year: 1953 end-page: 239 ident: B16 article-title: A serological recapitulation of human infection with different strains of influenza virus publication-title: Trans Assoc Am Physicians – volume: 86 start-page: 5774 year: 2012 end-page: 5781 ident: B52 article-title: Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes publication-title: J Virol doi: 10.1128/JVI.00137-12 – volume: 3 start-page: 521 year: 2013 end-page: 530 ident: B21 article-title: Influenza virus hemagglutinin stalk-based antibodies and vaccines publication-title: Curr Opin Virol doi: 10.1016/j.coviro.2013.07.007 – ident: B51 article-title: Code of Federal Regulations . 2002 . Title 45. Public welfare. Subtitle A. Department of Health and Human Services. Subchapter C. Administrative data standards and related requirements. Part 164. Security and privacy. Subpart E. Privacy of individually identifiable health information. 45 CFR 164.514 . https://www.govinfo.gov/content/pkg/CFR-2002-title45-vol1/pdf/CFR-2002-title45-vol1-sec164-514.pdf . – volume: 53 start-page: 51 year: 2018 end-page: 57 ident: B14 article-title: Development of next generation hemagglutinin-based broadly protective influenza virus vaccines publication-title: Curr Opin Immunol doi: 10.1016/j.coi.2018.04.001 – volume: 85 start-page: 10905 year: 2011 end-page: 10908 ident: B47 article-title: A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin publication-title: J Virol doi: 10.1128/JVI.00700-11 – volume: 8 start-page: 238 year: 2019 ident: B36 article-title: A complex dance: measuring the multidimensional worlds of influenza virus evolution and anti-influenza immune responses publication-title: Pathogens doi: 10.3390/pathogens8040238 – volume: 2019 start-page: 3053869 year: 2019 ident: B28 article-title: Improved specificity and false discovery rates for multiplex analysis of changes in strain-specific anti-influenza IgG publication-title: Comput Math Methods Med doi: 10.1155/2019/3053869 – volume: 14 year: 2008 ident: B22 article-title: Toward a unified nomenclature system for highly pathogenic avian influenza virus (H5N1) publication-title: Emerg Infectious Diseases doi: 10.3201/eid1407.071681 – volume: 346 start-page: 996 year: 2014 end-page: 1000 ident: B26 article-title: Antibody landscapes after influenza virus infection or vaccination publication-title: Science doi: 10.1126/science.1256427 – volume: 305 start-page: 371 year: 2004 end-page: 376 ident: B30 article-title: Mapping the antigenic and genetic evolution of influenza virus publication-title: Science doi: 10.1126/science.1097211 – volume: 85 start-page: 11048 year: 2011 end-page: 11057 ident: B49 article-title: Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including H3, H1, H2, and H5 publication-title: J Virol doi: 10.1128/JVI.05397-11 – volume: 212 start-page: 1270 year: 2015 end-page: 1278 ident: B40 article-title: High-affinity H7 head and stalk domain-specific antibody responses to an inactivated influenza H7N7 vaccine after priming with live attenuated influenza vaccine publication-title: J Infect Dis doi: 10.1093/infdis/jiv210 – volume: 211 start-page: 1408 year: 2015 end-page: 1417 ident: B24 article-title: Effect of influenza A(H5N1) vaccine prepandemic priming on CD4+ T-cell responses publication-title: J Infect Dis doi: 10.1093/infdis/jiu616 – volume: 108 start-page: 14216 year: 2011 end-page: 14221 ident: B48 article-title: Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1111497108 – volume: 206 start-page: 1069 year: 2012 end-page: 1077 ident: B7 article-title: Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes publication-title: J Infect Dis doi: 10.1093/infdis/jis402 – volume: 7 year: 2012 ident: B10 article-title: Evaluations for in vitro correlates of immunogenicity of inactivated influenza A H5, H7 and H9 vaccines in humans publication-title: PLoS One doi: 10.1371/journal.pone.0050830 – volume: 354 start-page: 722 year: 2016 end-page: 726 ident: B2 article-title: Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting publication-title: Science doi: 10.1126/science.aag1322 – volume: 198 start-page: 635 year: 2008 end-page: 641 ident: B11 article-title: Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant publication-title: J Infect Dis doi: 10.1086/590916 – volume: 104 start-page: 572 year: 1960 end-page: 578 ident: B15 article-title: On the doctrine of original antigenic sin publication-title: Proc Am Philos Soc – volume: 51 start-page: 398 year: 2019 end-page: 410.e5 ident: B39 article-title: Activation dynamics and immunoglobulin evolution of pre-existing and newly generated human memory B cell responses to influenza hemagglutinin publication-title: Immunity doi: 10.1016/j.immuni.2019.06.024 – volume: 489 start-page: 526 year: 2012 end-page: 532 ident: B46 article-title: Cross-neutralization of influenza A viruses mediated by a single antibody loop publication-title: Nature doi: 10.1038/nature11414 – volume: 117 start-page: 17957 year: 2020 end-page: 17964 ident: B45 article-title: Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1906613117 – volume: 86 start-page: 6970 year: 2012 end-page: 6978 ident: B1 article-title: A triclade DNA vaccine designed on the basis of a comprehensive serologic study elicits neutralizing antibody responses against all clades and subclades of highly pathogenic avian influenza H5N1 viruses publication-title: J Virol doi: 10.1128/JVI.06930-11 – volume: 19 start-page: 1732 year: 2001 end-page: 1737 ident: B6 article-title: Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans publication-title: Vaccine doi: 10.1016/S0264-410X(00)00395-9 – volume: 384 start-page: 1372 year: 2021 end-page: 1374 ident: B13 article-title: Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine publication-title: N Engl J Med doi: 10.1056/NEJMc2101667 – volume: 7 start-page: 46426 year: 2017 ident: B44 article-title: A formulated TLR7/8 agonist is a flexible, highly potent and effective adjuvant for pandemic influenza vaccines publication-title: Sci Rep doi: 10.1038/srep46426 – volume: 202 start-page: 335 year: 2019 end-page: 340 ident: B18 article-title: Original antigenic sin: how first exposure shapes lifelong anti-influenza virus immune responses publication-title: J Immunol doi: 10.4049/jimmunol.1801149 – volume: 106 start-page: 3877 year: 2009 end-page: 3882 ident: B41 article-title: Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0813390106 – volume: 111 start-page: 13133 year: 2014 end-page: 13138 ident: B35 article-title: Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1414070111 – volume: 352 start-page: 323 year: 2005 end-page: 325 ident: B3 article-title: The threat of an avian influenza pandemic publication-title: N Engl J Med doi: 10.1056/NEJMp048343 – volume: 28 start-page: 907 year: 2010 end-page: 915 ident: B12 article-title: B cell responses to H5 influenza HA in human subjects vaccinated with a drifted variant publication-title: Vaccine doi: 10.1016/j.vaccine.2009.11.002 |
SSID | ssj0000331830 |
Score | 2.3625112 |
Snippet | The antigenic shift and draft of hemagglutinin (HA) in influenza viruses is accepted as one of the major reasons for immune evasion. The analysis of B cell... Prime-boost vaccinations of humans with different H5 strains have generated broadly protective antibody levels. However, the effect of an individual's H5... Prime-boost vaccinations of humans with different H5 strains have generated broadly protective antibody levels. However, the effect of an individual’s H5... ABSTRACT Prime-boost vaccinations of humans with different H5 strains have generated broadly protective antibody levels. However, the effect of an individual’s... |
SourceID | doaj pubmedcentral proquest asm2 pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | e0044921 |
SubjectTerms | Adult Antibodies, Viral - blood Antibodies, Viral - immunology Antigenic Drift and Shift Cohort Studies H5 monovalent influenza vaccine (MIV) HA imprinting hemagglutinin (HA) antigenic distance Hemagglutinin Glycoproteins, Influenza Virus - immunology Humans Immunoglobulin G - blood Immunoglobulin G - immunology Influenza A Virus, H5N1 Subtype - genetics Influenza A Virus, H5N1 Subtype - immunology Influenza Vaccines - administration & dosage Influenza Vaccines - immunology influenza virus antibody landscape Influenza, Human - prevention & control Middle Aged original antigenic sin (OAS) Research Article Vaccination - methods Vaccines |
SummonAdditionalLinks | – databaseName: American Society for Microbiology Open Access dbid: AAUOK link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELaqVkhcEJRXClRGIE64ZB0ncY67VcsWBFSURb1ZfqVdqU2qJj0sP4FfzYzzEFtRiWPiiRN7Hpmxx98Q8tblZcl5XDKde8eEs5pJU06YgYYcWF64As8Of_mazRfi02l6ukH4cBamn8FmTzeXYSN_1GwuP1zOlvUebkEWDM-Ob6Xg7oNUb02ni2-fx5WVOEE5jQdAzdvPge2FvvnafyjA9f_Lx7ydKvnXv-fwIXnQO4102nH5Ednw1Ta515WRXD0mvyGW1u5iRb97HcwXPTr7CBch-9U3tK3pHLNekBwCfTpP6TGi-rNZXTctPerqlPzS9Ke2dtktD8LLPD0511feUbOi06pF2M6lpSF7zju0kNjxcSgLdkZPQq2J5glZHB782J-zvsYC06C6LSttovVEFkYaqZ3gRmfeQcwhROJlbkrrObQlOdcZ-Ao2NQ78CZhKb5zLbFYkT8lmVVf-OaEpF6VwmY954RD2zDiTg7-RlWlsNfjwEXmDE68GFqsQf3CpkD0qsEfxSUTeD3xRtocpxxFc3EX-biS_6vA57iKcIZNHIoTVDjdAyFSvpcomLtZpjgg_XIB10jDABJwgGLeRTsqIvB5ERIEa4t6KrjxwTkGcLYsY4cwi8qwTmfFVieAYhscRydeEae1b1luq5XmA-obwOwOTu_NfU_eC3OeYcRNWvF-Szfb6xr8Cl6k1u72O_AHMxBR5 priority: 102 providerName: American Society for Microbiology – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bb9MwFLbQEBIviDsZA3kC8YRH6jiJ84CmFTE6pKGJUbQ3y7d0lbpka4JE-Qn86p3jpGWdtjceW582sc_F30mOv0PIW5eXJedxyXTuHRPOaiZNOWAGBnJQeeEKPDt8-C0bjcXXk_TkH6VQv4DNjakd9pMaz2c7vy8Wu-DwH7sDMPLD2XBa7-CbyYLhkfK7sClxNPDDHumHoJyg8cZLls3rv4KArJszvrY5BQ7_m4Dn9frJKxvS_kPyoEeSdK9T_SNyx1ePyb2ut-TiCfkLCbZ2swX97nWIafRg8gU-hJJY39C2piMshUFxyP7pKKVHSPXPhnXdtPSga17yR9Of2tpp98wQLubp8ak-946aBd2rWuTynFoaSuq8w7CJf3wUeoVN6HFoQNE8JeP9zz8-jVjfeIFp8OeWlTbReiALI43UTnCjM-8gEREi8TI3pfUcxpKc6wwAhE2NA5ABS-mNc5nNiuQZ2ajqyr8gNOWiFC7zMS8ccqEZZ3IAIVmZxlYDsI_IG1x4tVS8CkkJlwrVo4J6FB9E5P1SL8r23OU4g9lt4u9W4ucdacdtgkNU8koIubbDF_V8onrXVTZxsU5zpP3hAkKWhgkmgIxg3kY6KSOyvTQRBb6JL1x05UFzCpJvWcTIcRaR553JrC6VCI65eRyRfM2Y1u5lfaSangb-b8jJM4jDm__j5l-S-xyrdMJT8i2y0c5_-VcAs1rzOjjQJbrsJ0Y priority: 102 providerName: Scholars Portal |
Title | Broadly Reactive IgG Responses to Heterologous H5 Prime-Boost Influenza Vaccination Are Shaped by Antigenic Relatedness to Priming Strains |
URI | https://www.ncbi.nlm.nih.gov/pubmed/34225490 https://journals.asm.org/doi/10.1128/mBio.00449-21 https://www.proquest.com/docview/2548905703 https://pubmed.ncbi.nlm.nih.gov/PMC8406322 https://doaj.org/article/c3d0a57738524531a6933218c5bb8d88 |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVABX databaseName: American Society for Microbiology Open Access customDbUrl: eissn: 2150-7511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000331830 issn: 2150-7511 databaseCode: AAUOK dateStart: 20100518 isFulltext: true titleUrlDefault: https://journals.asm.org/ providerName: American Society for Microbiology – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2150-7511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000331830 issn: 2150-7511 databaseCode: KQ8 dateStart: 20100101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Open Access Full Text customDbUrl: eissn: 2150-7511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000331830 issn: 2150-7511 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 2150-7511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000331830 issn: 2150-7511 databaseCode: DIK dateStart: 20100101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 2150-7511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000331830 issn: 2150-7511 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 2150-7511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000331830 issn: 2150-7511 databaseCode: GX1 dateStart: 20100101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2150-7511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000331830 issn: 2150-7511 databaseCode: RPM dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 2150-7511 dateEnd: 20250831 omitProxy: true ssIdentifier: ssj0000331830 issn: 2150-7511 databaseCode: M48 dateStart: 20100501 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELbQVkhcEJRXClRGIE6YZh0ncY67qO0WVKgoi_Zm-ZV2pTapmvSw_Qn8amac7GoXUXHhEinxKHE8Y3s-e_wNIe9cXpacxyXTuXdMOKuZNOWQGSjIQeWFK_Ds8PHXbDIVn2fpbC3VF8aEdfTAXcPt2cTFOs2RdIULMBidAQSHecmmxkgnwzFfmMbWwFQYgxO01XhJqsnl3uV4Xn_E7cuCIS_oQDeXfGMuCpT9f_Mz_wyXXJt_Dh6Rh73jSEddhR-Te77aJve7VJKLJ-QX4GntLhb0u9dhCKNHZ4dwEyJgfUPbmk4w8gXFAezTSUpPkNmfjeu6aelRl6vkVtOf2tp5t0QIH_P09FxfeUfNgo6qFqk755aGCDrvcJTEF5-E1GBn9DTkm2iekunB_o9PE9bnWWAaum_LSptoPZSFkUZqJ7jRmXeAO4RIvMxNaT2HsiTnOgN_ARregU8BTemNc5kFfTwjg6qu_AtCQUelcJmPeeGQ-sw4k4PPkZVpbDX48RF5iw2v-o7SqIBBuFSoHhXUo_gwIh-WelG2pyrHP7i4S_z9Svyq4-i4S3CMSl4JIbV2eAAGp3qDU_8yuIi8WZqIgq6I-yu68qA5BVhbFjFSmkXkeWcyq08lgiMUjyOSbxjTRl02S6r5eaD7BgiewbC78z8q_5I84BiUExbFX5FBe33jX4NX1ZpdsjUaTb992Q0dCa6HsyFcj4X8DT4iItA |
linkProvider | Directory of Open Access Journals |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Zb9QwEB5VWyF4QdyE0wjEEylZ53IedxFllx5UtIv6ZvlKu2ibVCQ8LD-BX82Mk12xFZV4TDyJY8-RGXv8DcAbm5cl51EZqtzZMLFGhUKXw1BjQ44sL2xBZ4cPDrPJLPl8mp5uQbY6C_Od6vIumh3VXPh9fFJsWoju6xGK9xfjeb1D25BFSOfHt1NeRHwA26PR7MveenUliklWoxWo5tXn0P5iB3zjX-Qh-__lZ15Nl_zr_7N7B273jiMbdZy-C1uuugc3ulKSy_vwG-NpZRdL9tUpb8LY9OwTXvgMWNewtmYTynwhcgz22SRlR4TsH47rumnZtKtV8kuxb8qYebdEiJ05dnyuLp1leslGVUvQnXPDfAads2Ql6cVHvjTYGTv29SaaBzDb_XjyYRL2dRZCherbhqWJlRqKQgstlE24VpmzGHckSexErkvjOLbFOVcZ-gsm1RZ9CpxKp63NTFbED2FQ1ZV7DCzlSZnYzEW8sAR9pq3O0efIyjQyCv34AF7TxMteURrpYxAuJLFHevZIPgzg3Yov0vRQ5TSCxXXkb9fklx1Gx3WEY2Lymoigtf0NlDTZa6o0sY1UmhPKD0_QQikcYIyOEI5bCytEAK9WIiJRFWl_RVUOOScx1hZFRJBmATzqRGbdVZxwCsWjAPINYdr4ls2Wan7u4b4xBM_Q7D75r6l7CTcnJwf7cn96uPcUbnHKwPEr4M9g0P746Z6jC9XqF72-_AHzzxjK |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELemTSBeEN8E2DAC8US21HES57FllJbBqBhFe7P8la3SllQkPJQ_gb96d05S0YlJPCa-OLHvI3f2-XeEvLFZUTAWFaHKnA25NSoUuhiEGhoyYHluczw7_OU4ncz5p9PkdIuk_VmYbgbrfVVf-o181OylLbp6hOLgcrSo9nEbMg_x_PhOwoQAad4ZDudfj9arK1GMshr1oJrXnwP7C_2zjX-Rh-z_l595PV3yr__P-B652zmOdNhy-j7ZcuUDcqstJbl6SP5APK3sxYp-c8qbMDo9-wgXPgPW1bSp6AQzX5Acgn06SegMkf3DUVXVDZ22tUp-K_pDGbNolwjhZY6enKuls1Sv6LBsELpzYajPoHMWrSR2PPOlwc7oia83UT8i8_GH7-8nYVdnIVSgvk1YmFipgci10EJZzrRKnYW4g_PYiUwXxjFoizOmUvAXTKIt-BQwlU5bm5o0jx-T7bIq3VNCE8YLblMXsdwi9Jm2OgOfIy2SyCjw4wPyGide9myWPgZhQiJ7pGePZIOAvOv5Ik0HVY4juLiJ_O2afNlidNxEOEImr4kQWtvfAEGTnaZKE9tIJRmi_DAOFkrBAGNwhGDcWlghAvKqFxEJqoj7K6p0wDkJsbbII4Q0C8iTVmTWr4o5w1A8Cki2IUwb37LZUi7OPdw3hOApmN1n_zV1L8nt2eFYfp4eHz0ndxgm4PgF8Bdku_n5y-2CB9XovU5drgD23hh4 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Broadly+Reactive+IgG+Responses+to+Heterologous+H5+Prime-Boost+Influenza+Vaccination+Are+Shaped+by+Antigenic+Relatedness+to+Priming+Strains&rft.jtitle=mBio&rft.au=Jiong+Wang&rft.au=Dongmei+Li&rft.au=Sheldon+Perry&rft.au=Shannon+P.+Hilchey&rft.date=2021-08-31&rft.pub=American+Society+for+Microbiology&rft.eissn=2150-7511&rft.volume=12&rft.issue=4&rft_id=info:doi/10.1128%2FmBio.00449-21&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_c3d0a57738524531a6933218c5bb8d88 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2150-7511&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2150-7511&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2150-7511&client=summon |